Humacyte (HUMA) Other financing activities (2020 - 2026)

Humacyte (HUMA) has reported Other financing activities for 7 consecutive years, with $30000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $30000.0 in Q2 2026; TTM through Jun 2026 was $35000.0, a 95.5% decrease from a year earlier, with the FY2025 full-year figure at $61000.0, down 95.96% from the prior year.
• Other financing activities was $30000.0 for Q2 2026 at Humacyte, up from $5000.0 in the prior quarter.
• Over five years, Other financing activities peaked at $787000.0 in Q2 2024 and troughed at $1000.0 in Q1 2022.
• A 5-year average of $180200.0 and a median of $99000.0 in 2023 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 15200.0% in 2022, down 99.51% in 2022.
• Over 5 years, Other financing activities stood at $306000.0 in 2022, then dropped by 17.32% to $253000.0 in 2023, then decreased by 10.28% to $227000.0 in 2024, then plunged by 97.8% to $5000.0 in 2025, then jumped by 500.0% to $30000.0 in 2026.
• The last three Other financing activities figures came in at $30000.0 (Q2 2026), $5000.0 (Q4 2025), and $56000.0 (Q1 2025), per Business Quant data.